Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 24, 2018First peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease
Today, Boston Scientific (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia™ Drug-Eluting Vascular...
-
Sep 22, 2018First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries
Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were...
-
Sep 21, 2018New Data at World Congress of Endourology Demonstrate the LithoVue Empower Device Improves OR Experience
Boston Scientific Corporation (NYSE: BSX) today announced the global launch of the LithoVue Empower™ Retrieval Deployment Device, designed to be used with the LithoVue™ Single-Use Digital...
-
Sep 17, 2018
Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the...
-
Sep 6, 2018Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the...